samedan logo

 
 
spacer
home > ebr > spring 2003 > catching the code
PUBLICATIONS
European Biopharmaceutical Review

Catching the Code

The evolving fields of genomics and proteomics are developing into essential tools in the discovery and development of new medicines. A wide variety of techniques have been developed which allow the detection of information ranging from a single nucleotide polymorphism (SNP) to complete expression profiles. Despite these advances there remains an ongoing drive to reduce the cost of research and development in order to minimise the expense of bringing a new drug or diagnostic to market. As such, there is increasing demand for large-scale bioassay analysis using smaller reagent volumes and at a lower cost per test. As a result a variety of 'multiplexing' technologies have emerged over the last few years which allow researchers to perform millions of parallel biological tests on a miniature scale.

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
By Dr Ciaran Sewter and Dr Mark Evans, Development Scientists, and Dr Elizabeth Hill, Chief Executive Officer at 3D Molecular Sciences Ltd

Dr Ciaran Sewter is a Development Scientist at 3D Molecular Sciences Ltd. He has a BSc in Biological Sciences from the University of East Anglia and a PhD from the University of Cambridge.

Dr Sewter has expertise in molecular and cell biology and has held a number of academic and industrial positions in obesity/diabetes research, immunology and virology.

Dr Mark Evans works as a Development Scientist at 3D Molecular Sciences Ltd. Having completed his first degree in Biochemistry at the University of Plymouth, Dr Evans obtained a PhD from the Department of Analytical Chemistry at Loughborough University, based on the development of biospecific assays for drugs of pharmaceutical interest. After two years as a Research Fellow, he became Head of Assay Automation at Kalibrant Ltd, before joining 3D Molecular Sciences in October 2002. His main areas of expertise are fluidics, instrumentation, automation, solid state devices and fluorescence.

Dr Elizabeth Hill is Chief Executive Officer and Co-Founder of 3D Molecular Sciences Ltd. She has 20 years' experience in the biotechnology, life sciences and health care sectors. Dr Hill started her career in instrumentation with Philips Scientific, subsequently moving into biotechnology, where she was a principal participant in the MBO of Enzymatix leading to Chiroscience and Celsis, and the subsequent IPO of the latter. She graduated with a First Class Honours degree in Chemistry and was awarded a PhD at King's College London for developing electrochemiluminescence as a detection technique for HPLC.
spacer
Dr Elizabeth Hill
spacer
spacer
spacer
Dr Mark Evans
spacer
spacer
spacer
Dr Sewter
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

Northway Biotechpharma enters into Development and Manufacturing Agreement with Synklino

Vilnius, Lithuania, and Copenhagen, Denmark – December 18th 2019 – Northway Biotechpharma, a leading biopharmaceutical Contract Development and Manufacturing Organization (CDMO), and Synklino, a company active in developing a therapeutic protein based therapy as treatment for cytomegalovirus (CMV) infection, announced today that they entered into a Development and Manufacturing Agreement for the recombinant fusion protein SYNx, which Synklino aims to bring into clinical trials.
More info >>

White Papers

The Importance of ADCC in Assessing Clinically Relevant Differences

Sartorius Stedim BioOutsource Ltd

Biosimilars have caused a revolution in the development of biologic drugs. The model for biosimilars is a combination of speed to market and low cost; these are fundamental to any biosimilar development project. The biosimilars pathway to approval is not always without difficulty, biosimilars are still relatively new, and as each new applicant is reviewed we are learning more and more about these molecules.
More info >>

 
Industry Events

12th World Meeting on Pharmaceutics, Biopharmaceutics and Pharmaceutical Technology

23-26 March 2020, Vienna, Austria

In continuation of the very successful scientific meetings in Budapest, Paris, Berlin, Florence, Geneva, Barcelona, Malta, Istanbul, Lisbon, Glasgow and Granada, the 12th PBP World will be held in Vienna from 23 – 26 March 2020. This every two year held conference has gained an ever increasing impact among the pharmaceutical scientists: With up to 1000 submitted abstracts and about 1300 participants it has become a well-established major meeting, attracting scientists from all over the world.
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement